stockrowANI Pharmaceuticals, Inc. (ANIP) vs Pacira BioSciences, Inc. (PCRX)
- ANI Pharmaceuticals, Inc. ANIP 68.56 −1.52%
- Pacira BioSciences, Inc. PCRX 36.44 +0.05%
ANI Pharmaceuticals, Inc. and Pacira BioSciences, Inc. are both Drug Manufacturers Specialty & Generic companies. ANI Pharmaceuticals, Inc. is the larger, with a market value of $1.6B against $1.5B — 1.1× the size. ANI Pharmaceuticals, Inc. trades at the lower P/E: 13.3× against 38.4×. ANI Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 25.9% against 3.70%. ANI Pharmaceuticals, Inc. has the higher net margin (11.2% vs 5.08%) and the higher return on invested capital (46.4% vs 5.37%). Across the 22 metrics below, ANI Pharmaceuticals, Inc. leads on 17 and Pacira BioSciences, Inc. on 5.
Valuation
Profitability
| Metric | ANIP | PCRX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 61.06% | 0.00% | 53.51% |
| Operating margin | 15.99% | 4.81% | 0.00% |
| Net margin | 11.22% | 5.08% | (2.45%) |
| Free cash flow margin | 19.72% | 22.74% | 0.00% |
| Return on equity | 20.45% | 5.24% | (0.80%) |
| Return on assets | 7.85% | 3.02% | (1.67%) |
| Return on invested capital | 46.43% | 5.37% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack